Proton pump inhibitor therapy for eosinophilic esophagitis: History, mechanisms, efficacy, and future directions

Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International C...

Descripción completa

Detalles Bibliográficos
Autores: Franciosi, James P., Mougey, Edward B., Dellon, Evan S, Gutiérrez Junquera, Carolina, Fernández-Fernández, Sonia, Venkatesh, Rajitha D, Gupta, Sandeep K
Tipo de recurso: artículo
Fecha de publicación:2022
País:España
Institución:Universidad Autónoma de Madrid
Repositorio:Biblos-e Archivo. Repositorio Institucional de la UAM
Idioma:inglés
OAI Identifier:oai:repositorio.uam.es:10486/712718
Acceso en línea:http://hdl.handle.net/10486/712718
https://dx.doi.org/10.2147/JAA.S274524
Access Level:acceso abierto
Palabra clave:eosinophilic esophagitis
EoE
proton pump inhibitor medication
PPI
precision medicine
Medicina
Descripción
Sumario:Over the past decade, the role of proton pump inhibitor (PPI) medication has evolved from a diagnostic tool for Eosinophilic Esophagitis (EoE), by excluding patients with PPI responsive esophageal eosinophilia (PPI-REE), to a therapy for EoE. This transition resulted from the Updated International Consensus Diagnostic Criteria for Eosinophilic Esophagitis: Proceedings of the Appraisal of Guidelines for Research and Evaluation II (AGREE) Conference to support PPI therapy for EoE in children and adults. Additional recent advances have suggested a role for genetic variations that might impact response to PPI therapy for EoE. This review article will explore a brief background of EoE, the evolution of PPI therapy for EoE and its proposed mechanisms, efficacy and safety in children and adults, and considerations for future PPI precision medicine in patients with EoE